247 related articles for article (PubMed ID: 18501085)
1. Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin.
Soloman R; Gabizon AA
Clin Lymphoma Myeloma; 2008 Feb; 8(1):21-32. PubMed ID: 18501085
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.
Gabizon A; Shmeeda H; Barenholz Y
Clin Pharmacokinet; 2003; 42(5):419-36. PubMed ID: 12739982
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
[TBL] [Abstract][Full Text] [Related]
4. New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy.
Gabizon AA; Patil Y; La-Beck NM
Drug Resist Updat; 2016 Nov; 29():90-106. PubMed ID: 27912846
[TBL] [Abstract][Full Text] [Related]
5. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours.
Gabizon A; Martin F
Drugs; 1997; 54 Suppl 4():15-21. PubMed ID: 9361957
[TBL] [Abstract][Full Text] [Related]
6. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological basis of pegylated liposomal doxorubicin: impact on cancer therapy.
Gabizon A; Shmeeda H; Grenader T
Eur J Pharm Sci; 2012 Mar; 45(4):388-98. PubMed ID: 21933707
[TBL] [Abstract][Full Text] [Related]
8. [Chinese expert consensus on management of adverse events of pegylated liposomal doxorubicin (2020 edition)].
Breast Cancer Group, Chinese Association for Clinical Oncologist (CACO)
Zhonghua Zhong Liu Za Zhi; 2020 Aug; 42(8):617-623. PubMed ID: 32867451
[TBL] [Abstract][Full Text] [Related]
9. [Doxil--pegylated liposomal doxorubicin].
Sekiya N; Imamura A
Gan To Kagaku Ryoho; 2008 Aug; 35(8):1439-43. PubMed ID: 18701868
[TBL] [Abstract][Full Text] [Related]
10. Extracorporeal Elimination of Circulating Pegylated Liposomal Doxorubicin (PLD) to Enhance the Benefit of Cytostatic Therapy in Platinum-Resistant Ovarian Cancer Patients.
Kubeček O; Bláha M; Diaz-Garcia D; Filip S
Acta Medica (Hradec Kralove); 2015; 58(1):3-8. PubMed ID: 26454800
[TBL] [Abstract][Full Text] [Related]
11. Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage.
Shmeeda H; Tzemach D; Mak L; Gabizon A
J Control Release; 2009 Jun; 136(2):155-60. PubMed ID: 19331844
[TBL] [Abstract][Full Text] [Related]
12. Histological evidence for the cardiac safety of high-dose pegylated liposomal doxorubicin in a patient with HIV-associated Kaposi sarcoma: a case report and literature review.
Ishihara A; Hatakeyama S; Suzuki J; Amano Y; Sasahara T; Toshima M; Morisawa Y
BMC Infect Dis; 2019 Oct; 19(1):848. PubMed ID: 31615436
[TBL] [Abstract][Full Text] [Related]
13. Pegylated liposomal doxorubicin: a guide to its use in various malignancies.
Lyseng-Williamson KA; Duggan ST; Keating GM
BioDrugs; 2013 Oct; 27(5):533-40. PubMed ID: 24018470
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer.
Rom J; Bechstein S; Domschke C; Golatta M; Mayer C; Heil J; Thum J; Smetanay K; Windemuth-Kieselbach C; Wallwiener M; Marme F; Schuetz F; Sohn C; Schneeweiss A
Anticancer Drugs; 2014 Feb; 25(2):219-24. PubMed ID: 24247203
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and toxicity considerations for the use of anthracyclines in ovarian cancer treatment.
Morotti M; Valenzano Menada M; Venturini PL; Ferrero S
Expert Opin Drug Metab Toxicol; 2011 Jun; 7(6):707-20. PubMed ID: 21434836
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin-conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse and rat tumor models.
Kaminskas LM; McLeod VM; Kelly BD; Cullinane C; Sberna G; Williamson M; Boyd BJ; Owen DJ; Porter CJ
Mol Pharm; 2012 Mar; 9(3):422-32. PubMed ID: 22233281
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin.
Petersen GH; Alzghari SK; Chee W; Sankari SS; La-Beck NM
J Control Release; 2016 Jun; 232():255-64. PubMed ID: 27108612
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
[TBL] [Abstract][Full Text] [Related]
19. Role of pegylated lyposomal doxorubicin (PLD) in systemic Kaposi's sarcoma: a systematic review.
Di Trolio R; Di Lorenzo G; Delfino M; De Placido S
Int J Immunopathol Pharmacol; 2006; 19(2):253-63. PubMed ID: 16831292
[TBL] [Abstract][Full Text] [Related]
20. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy.
Gabizon AA
Cancer Invest; 2001; 19(4):424-36. PubMed ID: 11405181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
